Wei Hong

机构：Zhejiang Cancer Hospital · ORCID：0000-0002-8359-9703

发表论文 40 篇 · 总被引 138 次 · h-index 6

代表论文

• Trastuzumab rezetecan, a HER2-directed antibody–drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study (2025 · The Lancet Oncology · 被引 52)
• Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study (2025 · Clinical Cancer Research · 被引 13)
• A narrative review on advances in neoadjuvant immunotherapy for esophageal cancer: Molecular biomarkers and future directions (2024 · International Journal of Cancer · 被引 9)
• An Open‐Label, Single‐Arm, Phase II Trial of Sintilimab Plus Anlotinib for Metastatic Non‐Small Cell Lung Cancer After First‐Line PD ‐(L)1 Inhibitor (2025 · Cancer Medicine · 被引 3)
• Timing of immune checkpoint inhibitor infusion predicts survival in advanced esophageal squamous cell carcinoma: A retrospective cohort study (2026 · Therapeutic Advances in Medical Oncology)
• Figure 1 from Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study (2025)